RT Journal Article
SR Electronic
T1 Smoking in social housing among adults in England, 2015-2020: a nationally representative survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.11.22269062
DO 10.1101/2022.01.11.22269062
A1 Jackson, Sarah E.
A1 Cheeseman, Hazel
A1 Arnott, Deborah
A1 Titmarsh, Robbie
A1 Brown, Jamie
YR 2022
UL http://medrxiv.org/content/early/2022/01/11/2022.01.11.22269062.abstract
AB Objectives To analyse associations between living in social housing and smoking in England and evaluate progress toward reducing disparities in smoking prevalence among residents of social housing compared with other housing types.Design Nationally-representative, cross-sectional survey between January 2015 and February 2020.Setting England.Participants 105,562 adults (≥16y).Primary and secondary outcome measures Linear and logistic regression were used to analyse associations between living in social housing (vs. other housing types) and smoking status, cigarettes per day, time to first cigarette, exposure to smoking by others, motivation to stop smoking, quit attempts, and use of cessation support. Analyses adjusted for sex, age, social grade, region, and survey year.Results Adults living in social housing had twice the odds of being a smoker (ORadj=2.17, 95%CI 2.08- 2.27), and the decline in smoking prevalence between 2015 and 2020 was less pronounced in this high-risk group (−7%; ORadj=0.98, 95%CI 0.96-1.01) than among adults living in other housing types (− 24%; ORadj=0.95, 95%CI 0.94-0.96; housing tenure*survey year interaction p=0.020). Smokers living in social housing were more addicted than those in other housing (smoking within 30 minutes of waking: ORadj=1.50, 95%CI 1.39-1.61), but were no less motivated to stop smoking (ORadj=1.06, 95%CI 0.96-1.17) and had higher odds of having made a serious attempt to quit in the past year (ORadj=1.16, 95%CI 1.07-1.25). Among smokers who had tried to quit, those living in social housing had higher odds of using evidence-based cessation support (ORadj=1.22, 95%CI 1.07-1.39) but lower odds of remaining abstinent (ORadj=0.63, 95%CI 0.52-0.76).Conclusions There remain stark inequalities in smoking and quitting behaviour by housing tenure in England, with declines in prevalence stalling between 2015 and 2020 despite progress in the rest of the population. In the absence of targeted interventions to boost quitting among social housing residents, inequalities in health are likely to worsen.Strengths and limitations of this study A major strength of this study was the large sample, which was representative of adults living in England.Another strength was the broad range of smoking outcomes assessed, offering a detailed view of smoking behaviour among people living in social housing compared with those living in other housing types.The main limitation was that all outcomes were self-reported, introducing scope for bias.Competing Interest StatementJB has received unrestricted research funding from Pfizer, who manufacture smoking cessation medications. All authors declare no financial links with tobacco companies or e-cigarette manufacturers or their representatives.Funding StatementThis work was supported by Cancer Research UK (C1417/A22962).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the STS was granted by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymised when received by UCL.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request from the corresponding author.